Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Macugen, C0X-2 Updates Expected At Nov. 30 Analyst Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

The meeting is expected to focus on Pfizer's pipeline, including the inhaled insulin Exubera and insomnia agent indiplon. Pfizer will likely discuss safety profile of its COX-2 inhibitors.

You may also be interested in...



Crestor, Serevent Are Among Problem Drugs Cited By FDA Safety Reviewer

FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx

Celebrex Cardiovascular Safety Supported In FDA/Kaiser Study

FDA releases data from COX-2 cardiovascular safety study that was included in a Sept. 30 internal memo to Office of Drug Safety Director Seligman. The study shows Celebrex patients have lower cardiovascular safety risk compared to remote NSAID users.

Exubera Partnership In Doubt: Pfizer, Sanofi In Litigation Over Inhaled Insulin

Pfizer is seeking to enforce "change-in-control" provisions in the Exubera co-marketing agreement. Sanofi-Aventis says it "has no idea" if Pfizer's goal is to buy out the partnership or force a sale to Sanofi.

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel